Pharmacokinetic study of chloramphenicol in patients with liver disease.
The pharmacokinetics of intravenous chloramphenicol has been studied in 42 patients with liver disease and in 8 controls. The half-life of chloramphenicol (t 1/2) was increased in the various liver disorders, the metabolic clearance rate (MCR) and apparent volume of distribution (Vd) were decreased and the area under the time - concentrations curve (AUC) showed an increase. The t 1/2 of chloramphenicol showed a significant correlation with serum albumin and prothrombin time index.
D000208:Acute Disease; D000328:Adult; D006502:Budd-Chiari Syndrome / Q000378:metabolism; D002701:Chloramphenicol / Q000097:blood / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006505:Hepatitis / Q000378:metabolism; D006801:Humans; D006975:Hypertension, Portal / Q000378:metabolism; D007700:Kinetics; D008101:Liver Abscess, Amebic / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism; D008107:Liver Diseases / Q000378:metabolism*; D008111:Liver Function Tests; D008297:Male; D011169:Portal Vein; D014652:Vascular Diseases / Q000378:metabolism
D002701:Chloramphenicol